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Background: Diabetic foot problems and their complications are a medical and economic challenge to the health care
system and require an aggressive multidisciplinary approach to achieve limb salvage. The goals of this review article are
to delve into this comprehensive topic and summarize key points regarding diabetic foot problems from the perspective
of the vascular specialist treating these patients.
Methods: The MEDLINE database was searched to identify articles on this topic.
Results: We found 112 relevant articles. These were used to provide current data on (1) the pathogenesis leading to
diabetic foot lesions (ie, the etiologic triad of ischemia, neuropathy, and infection), (2) the clinical presentation of these
foot lesions and their systemic manifestations, (3) the optimal methods of diagnostic evaluation, including noninvasive
testing and arteriography, (4) treatment selection guidelines to help delineate which patients require revascularization,
and (5) medical and interventional treatments, including prevention strategies, wound healing strategies, use of
antibiotics, and endovascular and open surgical options for revascularization.
Conclusions:The data presented in this review article allow vascular clinicians to optimize patient care and achieve effective
limb salvage for this growing segment of the population. (J Vasc Surg 2010;51:476-86.)Despite refinements in medical and surgical care during
the past decade, foot problems in diabetic patients remain a
major public health issue and are the most common reason
for hospitalization of a diabetic patient. A foot complica-
tion severe enough to require hospitalization will develop
in approximately 15% of the nearly 24 million diabetic
patients in the United States (U.S.) during their lifetime.1
Because this small group of people with diabetes—only
7.8% of the U.S. population—accounts for 60% of all
nontraumatic lower extremity amputations,2 public health
initiatives have focused on aggressive treatment of diabetic
foot infections to halt the escalating number of amputa-
tions. Despite these widespread efforts, the annual financial
costs relating to infection, ulceration, and amputation have
increased to $10 billion nationwide.3 This increase has
occurred even while many institutions have successfully
adopted the recommended multidisciplinary approach to
care for diabetic patients.4,5
EPIDEMIOLOGY
The lifetime risk that a diabetic patient will acquire foot
lesions (ulcers/gangrene) has been estimated at 15% to 25%,
with an annual incidence of 1.0% to 4.1%.6 The incidence of
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476these lesions appears similar in type 1 vs type 2 diabetic
patients, although type 2 diabetic patients comprise approxi-
mately 90% of the total diabetic population. In15% of these
patients, ulcers will ultimately lead to amputation.7
The risk for an initial foot ulcer is increased in patientswho
have had diabetes for10 years, aremale, have poor glycemic
control, and already have other cardiovascular, renal, or retinal
comorbidities.8 Foot ulcers occur in different rates in different
parts of the world and rates of amputations differ as well, with
the highest inNative Americans and lowest inMadrid, Spain.9
Specifically inNorth America, foot ulcers and amputations are
more common in ethnicminority groups, especiallyHispanics
and African Americans, as well as in other groups of patients
who lack health insurance.9
PATHOGENESIS
Ischemia, neuropathy, and infection are the three
pathologic components that lead to diabetic foot compli-
cations, and they frequently occur together as an etiologic
triad. The most important principle in treating foot isch-
emia in patients with diabetes is recognition that the etiol-
ogy of this ischemia is macrovascular occlusion of the leg
arteries due to atherosclerosis.
For many decades, clinicians mistakenly ascribed to the
theory of “small vessel disease,” or microvascular occlusion
of arterioles, as the cause of ischemic complications. This
theory directly caused the widespread erroneous opinion
that patients with diabetes and ulcers would absolutely
need amputations because revascularization was not possi-
ble. The idea originated from a single histologic study of
amputated limbs from diabetic patients, whereby a material
positive for periodic acid-Schiff occluded the arterioles.10 A
subsequent prospective study11 of amputation specimens,
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 2 Kalish and Hamdan 477however, refuted the notion of an arteriolar occlusive lesion
associated with diabetes. It is now well-recognized that
diabetic patients typically have tibial and peroneal arterial
occlusive disease with relative sparing of the foot arteries,
and ischemia results from atherosclerotic macrovascular
disease as well as from microcirculatory dysfunction.12
Diabetic neuropathy has multiple manifestations in the
foot because it encompasses sensory, motor, and autonomic
fibers. The pathogenesis of diabetic neuropathy is not fully
understood. Possible explanations are based on theories of
alterations in the vasa nervorum or abnormalities in metabo-
lism. The vascular theory relates to thickening of the nutrient
vessels that may occlude with progression, resulting in isch-
emic injury to the nerve. A more popular theory is the in-
creased activity of the polyol (sorbitol) pathway.13 Accumula-
tion of sorbitol has been shown in aortic intima and media.
Excess sorbitol may produce toxic effects, resulting in demy-
elination and impaired velocity of peripheral nerve conduc-
tion. These pathologic findings have been reported in human
diabetic neuropathy.14
Sensory neuropathy affects the small-diameter pain and
temperature fibers first, and susceptibility to injury is increased
because these patients are less sensitive to pressure-related
trauma or otherminor skin injuries.Motor neuropathy affects
the longer fibers that innervate the foot, affecting both the
intrinsic footmuscles and legmuscles. Autonomic neuropathy
causes dry skin through the loss of sweat and oil gland func-
tion. Dry skin carries an increased susceptibility to breakdown
and fissures, thus creating a portal of entry for bacteria. Over-
all, neuropathy results in a series of predictable structural
changes in the foot that predispose to ulceration.
Although there are generally no fixed occlusive lesions of
the small foot vessels, this does not imply thatmicrocirculatory
dysfunction does not exist. Neuropathy leads to a shunting
away of the blood through arteriovenous connections in the
microcirculation.15 This results in decreased tissue perfusion,
even in the presence of normal arterial supply. Oxygen satu-
ration is reduced in the skin of diabetic patients, and this
impairment is accentuated in the presence of neuropathy.16,17
Diabetes causes structural and functional changes within
the arteriolar and capillary systems as well, notably, thickening
of the basement membrane.18 This thickened membrane
impairs the migration of leukocytes and hampers the normal
hyperemic or vasodilatory response to injury, thus simulta-
neously increasing the susceptibility to injury while also blunt-
ing the typical manifestations of such an injury.19 Because of
this blunted neuroinflammatory response, diabetic patients
lack a crucial component of the body’s natural first-line of
defense against pathogens and thus aremore susceptible to an
ensuing foot infection.20
CLINICAL PRESENTATION
The clinical presentation of peripheral arterial disease
(PAD) encompasses intermittent claudication, rest pain,
and ulcers, with or without gangrene. Diabetic patients
may exhibit these typical symptoms but more often, they
present with a wound that fails to heal or with pain at the
site of a callus, pressure point, or other bony prominence.Although diabetes alone increases the prevalence of symp-
tomatic PAD by 3.5-fold in men and 8.6-fold in women,21
the largest risk attributed to diabetic patients is for nontrau-
matic amputation, which increases 8-fold in all patients
aged 45,22 12-fold in all patients aged 65, and 23-fold
for those aged 65-74 years.23 A thorough clinical examina-
tion of foot ulcers is necessary to evaluate the depth and
extent of involvement, anatomic location, etiology, and
presence of ischemia or infection.
On inspection, the neuropathic foot often has a char-
acteristic appearance. The atrophy of the intrinsic foot
muscles allows the strong flexormuscles to draw up the toes
in a “clawed” position, and new pressure points emerge at
the tips of the toes and the prominent metatarsal heads.
The skin is usually dry or cracked due to the loss of sweating
and oil secretion. Heavy, thick callus, which may ulcerate
over time, is often abundant at points of increased pressure
and weight bearing. Atrophy of small muscles of the foot
may or may not be apparent.
Color and temperature changes can range from hyper-
emic and warm in a patient with an acute Charcot fracture, to
pale and cool in a patient with concomitant ischemia and
neuropathy. In the presence of arteriovenous shunting, an
ischemic footmay appear pink and relatively warm evenwith a
significant loss of arterial perfusion. In individuals with a
Charcot foot, which is a progressive and degenerative arthrop-
athy of single or multiple joints that ultimately leads to de-
struction of normal foot architecture, collapse of the arch, a
“rocker bottom” deformity, or other abnormalities may be
seen.
The neuropathic pain syndrome is not completely under-
stood but may also be a clinical presenting symptom.24 This
manifestation of neuropathy is a component of impaired glu-
cose tolerance and the metabolic syndrome, and as such, new
symptomatic treatments with medications other than gabap-
entin have recently been approved (duloxetine hydrochloride
and pregabalin).25 A summary of the larger randomized,
controlled trials is presented in Table I.26-31 Although each of
these trials points to the superiority of the tested drug vs
placebo, the absolute clinical effectiveness of this pharmaco-
therapy is still unknown.
The typical inflammatory signs of infection, including
erythema, rubor, cellulitis, or tenderness, may be absent or
diminished. Also frequently absent are the usual systemic
manifestations of infection, including fever, tachycardia, or
elevated white blood cell count.32,33 Unexplained hyper-
glycemia should prompt an aggressive search for a source of
infection because the patient’s elevated glucose level may
be the only sign of impending problems.
Careful palpation of the foot for areas of tenderness or
fluctuance is important to detect undrained abscesses in
deeper tissue planes. All ulcers must be carefully inspected
and probed, and superficial eschar unroofed, to look for
potential deep space abscesses.
Ulcers and infections have been characterized by nu-
merous classification systems that attempt to predict treat-
ment failure or resulting amputations.34 These classifica-
tion schemes divide infections into mild (superficial and
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signs or symptoms of infection, or metabolic derange-
ments). The only relevance for the clinician is to determine
if a patient’s infection is limb- or life-threatening and then
determine the appropriate course of treatment (outpatient
management, hospitalization, débridement, or amputa-
tion). Although only 10% to 15% of diabetic patients will
develop a foot infection during their lifetime, those infec-
tions range from mild (47%) to moderate (34%) to severe
(18%).35 Hospitalization, minor amputation, and major
amputation rates vary significantly by the extent of infec-
tion (mild, 4.2%, 2.8%, 0%; moderate, 52%, 23%, 23%; and
severe, 89%, 48%, 30%).35
DIAGNOSTIC EVALUATION
The presence of neuropathy can usually be determined
by taking a careful patient history and physical examination.
Loss of pin-prick sensation can be determined by the use of
a Semms-Weinstein monofilament, a nylon monofilament
attached to a plastic handle, which is applied under pressure
to a patient’s foot and assesses the level of sensation at 10
different dermatome points. In multiple prospective stud-
ies, this instrument has identified patients at risk for foot
ulceration with a sensitivity ranging from 66% to 91% and a
specificity ranging from 34% to 86%.6 Vibratory sensation is
tested with a tuning fork, although this is less predictive of
ulceration than the Semms-Weinstein monofilament.
Nerve conduction or electromyelography studies are not
essential.
Osteomyelitis occurs after the spread of superficial in-
fection of the soft tissue to the adjacent bone or marrow.36
Table I. Summary of randomized, controlled clinical trial
First author Medications (vs placebo)
Patients
(total)
Backonja,26 1998 Gabapentin (900-3600 mg/d) 165
Serpell,27 2002 Gabapentin (up to 2400 mg/d) 305
Lesser,28 2004 Pregabalin (75-600 mg/d) 338
Tolle,29 2008 Pregabalin (150-600 mg/d) 395
Wernicke,30 2006 Duloxetine (60-120 mg/d) 334
Raskin,31 2005 Duloxetine (60-120 mg/d) 348Although numerous expensive radiologic techniques areavailable to diagnose osteomyelitis, a simple sterile metallic
probe will usually suffice.37 Probing the ulcer determines
the ulcer depth and extent and thus determines the involve-
ment of bony structures.38 Grayson et al39 revealed that if
this sterile probe hits bone, then osteomyelitis can be
diagnosed with a sensitivity of 66%, a specificity of 85%, and
a positive predictive value of 89%.
Plain radiographs of the foot should be obtained in
every patient with suspected foot infection. X-ray images
can reveal the presence of a foreign body, gas, osteolysis, or
joint effusion, as well as delineate anatomy for surgical
planning. A bone scan or tagged white blood cell scan
should be reserved for cases in which the metal probe test is
equivocal, when an abscess or multifocal disease is sus-
pected, or in patients with Charcot foot because the asso-
ciated bony changes and inflammatory response can be
misinterpreted as osteomyelitis. Magnetic resonance imag-
ing is a highly sensitive diagnostic tool (up to 100%) but is
only about 80% specific because osteomyelitis and fracture
may have similar appearances.40 The conclusive diagnosis
of osteomyelitis can be obtained by bone biopsy, but this is
rarely necessary.41
A complete vascular examination is imperative in any
patient reporting symptoms consistent with claudication or
rest pain, although many diabetic patients who require
revascularization will present with limb-threatening isch-
emia and have no antecedent vascular symptoms. These
patients will present with a nonhealing ulcer with or with-
out associated gangrene or infection. Some patients are
referred after a minor surgical procedure when the foot fails
luating pharmacotherapy for painful diabetic neuropathy
ment
tion Reported results of drug vs placebo
ks 2Mean daily pain score (P  .001)
1 Quality of life (P  .01)
1 Adverse events: dizziness (24% vs 5%, P  .001);
somnolence (23% vs 6%, P  .04); confusion (8% vs
1.2%, P  .06)
ks 2 Daily pain score from 21% to 14% (P  .048)
1 Quality-of-life questionnaire scores
ks 2Mean pain score with 300-mg  600-mg dose
(P  .0001)
Responders (50%2 pain score) in 46% vs 18%
Improved pain and sleep scores as early as 1 week
ks Responders (50%2 pain score) in 46% vs 30%
(P  .036) at 600 mg
Improved scores at 600 mg for sleep interference,
quality-of-life models, and global impression of
change
ks Rapid onset of action; pain improvements starting at
1 week
No difference in 60- vs 120-mg dosing
ks Significant improvement of 24-hour pain score
(P  .001)
Discontinuation due to adverse events: 12.1% for 120
mg/d vs 2.6% placebos eva
Treat
dura
8 w
8 w
5 w
12 w
12 w
12 wto heal due to ischemia.
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noninvasive vascular laboratory studies are particularly
useful. Patients with severe ischemia usually have ankle-
brachial indices (ABI) of 0.4. The resting ABI may be
normal in certain patients with claudication, and exercise
testing may reveal that up to 31% of these patients then
manifest a change in the ABI.42 Many diabetic patients,
however, will have artificially elevated ankle pressures due
to calcification of the arterial wall,43 the so-called noncom-
pressible vessel. In this scenario, 250 mm of pressure is
required, and the resultant ABI will underestimate the
prevalence of arterial disease in this population.44 Pulse
volume recordings are then required. Some centers have
found toe pressures43 and transcutaneous oxygen measure-
ments45 to be useful in diabetic patients.
Intra-arterial digital subtraction arteriography is the
most accurate method to evaluate the lower extremity
arterial circulation. Although magnetic resonance arteriog-
raphy had been used more frequently during the past
decade in patients with marginal renal function,46 recent
reports detailing nephrogenic systemic fibrosis47 have
shifted clinical practice back to conventional arteriography.
A carefully performed arteriogrammust show the appropri-
ate inflow source and outflow target artery and must incor-
porate the complete infrapopliteal circulation, including
foot vessels.
Diabetic patients are at higher risk of contrast-induced
nephropathy (CIN) after arteriography, regardless of their
baseline creatinine level (although the combination of dia-
betes and chronic kidney disease carries an even higher risk
of CIN).48,49 However, the risk of CIN can be minimized
by prehydration with sodium bicarbonate solution50 and
by using an isosmolar contrast such as Visipaque (GE
Healthcare, Princeton, NJ).49,51,52 The addition of N-
acetylcysteine has not been definitively proven.53 Selective
catheterizations of the superficial femoral or popliteal artery
allow excellent imaging of the foot vessels with a much
reduced contrast load.
TREATMENT SELECTION
The most important principle driving all of this testing
is to answer the difficult question of whether revasculariza-
tion is needed for a certain lesion, for a certain patient.
Some patients with very minimal and very distal gangrene
and who have adequate pulse volume recordings or toe
pressures may be candidates for a partial toe amputation
without revascularization. Unfortunately, the limitations of
noninvasive testing in these circumstances mainly center on
the poor predictive value of adequate healing: pulse volume
recording can predict failure in up to 50% of patients whose
minor amputation would eventually heal, and vice versa.54
In the absence of deep infection or necrosis, minor
infections or ulcers may be managed conservatively with
local wound care, antibiotics, or both. On the other hand,
noninvasive testing adds little information to the evaluation
of a patient with more advanced foot ischemia and the
absence of a palpable foot pulse. In these patients, contrastarteriography should be performed as the first diagnostic,
and potentially therapeutic, test.
For patients who require revascularization of lower
extremity occlusive disease, critical decisions need to be
made about traditional surgical reconstruction vs less inva-
sive endovascular interventions. Although the choice be-
tween these two treatment modalities is outside the scope
of this review, various reasons exist in favor of and against
both methods. Certain patients may not be appropriate
candidates for arterial reconstruction because of their over-
all health status. Elderly patients with severe dementia who
are nonambulatory or bedridden, or who have severe flex-
ion contractures of the knee or hip, have no prospect of
rehabilitation and are inappropriate candidates for tradi-
tional vascular procedures. Age alone, however, is not a
contraindication for arterial reconstruction.55,56 Patients
with terminal cancer with a very short life expectancy or
similar lethal comorbidities do poorly with open revascu-
larization and are probably better served by endovascular
intervention or primary amputation. Patients with an un-
salvageable foot due to extensive necrosis from ischemia or
infection also require primary amputation.
In patients with salvageable ischemic foot lesions and
concomitant active infection, the infection needs to be
controlled before vascular surgical intervention. In addition
to instituting broad-spectrum antibiotics, options include
open débridement and drainage or partial foot amputation.
A short delay (usually 5 days) before revascularization to
control active infection is justified; however, longer waits to
“sterilize wounds” is inappropriate and may result in fur-
ther necrosis and a lost opportunity to save the foot.57
During this intervening period, contrast arteriography and
other preoperative evaluations can be performed as neces-
sary. Once cellulitis, lymphangitis, and edema have im-
proved or resolved, especially in any areas of expected
incisions for bypass, bypass can be undertaken without
further delay.
On the other hand, in the absence of active infection,
eschars may function as the body’s natural “biologic dress-
ing,” and débridement of these noninfected areas of super-
ficial gangrene may worsen the chances of limb salvage by
creating larger open wounds in the setting of ischemia. This
is especially true in cases of heel ulcers because of poor
circulation in the heel fat pad as well as the danger of
debriding into the calcaneus and thus fostering wound
contraction instead of healthy granulation tissue. Although
authors report complete healing rates of heel gangrene in
70% to 85% of patients6months with aggressive débride-
ment and revascularization,58,59 other studies point to the
significant morbidity and poor healing rates once a calca-
nectomy is required for adequate débridement.60 Overall,
careful patient selection is extremely important to deter-
mine which patients should have revascularization vs pri-
mary amputation.
MEDICAL TREATMENTS
Primary prevention should be the first tenet of manag-
ing the diabetic foot, but secondary prevention with metic-
sk.
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prevention involves aggressive glycemic control (goal he-
moglobin A1C 6.5% to 7.0%); management of associated
risk factors such as smoking, hypertension, hyperlipidemia,
and obesity; periodic physical examinations, including a
vascular examination; and probablymost important, proper
foot care and hygiene strategies.6 Although the absolute
success rate of preventing ulcers and amputations has never
been fully quantified using thesemeasures, most authorities
agree on the usefulness of these strategies.6 Furthermore,
foot care behaviors are improved significantly at 12 months
with aggressive education strategies in high-risk groups of
diabetic patients.62
The first step in the treatment of any neuropathic ulcer
is restriction of weight bearing of the involved extremity.
Patients with limb-threatening foot infections and non-
compliant patients will require hospitalization and bedrest,
followed by evaluation and management of arterial isch-
emia. Uncomplicated neuropathic ulcers will often heal
with topical therapy and nonweight bearing, and a trial of
outpatient care is warranted. Topical dressings should be
aimed at maintaining a moist environment with saline-
impregnated gauze, topical antibiotic ointments, or other
similar agents. The ulcer should be protected from exces-
sive pressure by placing of an accommodative pad around
the lesion to distribute pressure to surrounding tissues.
Heavy callus around the edges of the lesion should be
trimmed away to reduce peak plantar pressure, and shoes
should be replaced with a stiff-soled “healing sandal.”
Custom-molded orthotics and extra-depth shoes, running
shoes, or custom-molded shoes in the case of severe foot
deformity, are also prescribed to prevent future recur-
rence.63
Hyperbaric oxygen therapy has received much atten-
Table II. Summary of randomized trials comparing hyper
Author Patients
Faglia,64 1996 5 HBOT  standard wound care
33 standard wound care
Abidia,65 2003 8 HBOT
8 control (air)
Kessler,66 2003 14 HBOT  standard wound care
14 standard wound care
Duzgun,67 2008 50 HBOT  standard wound care
50 standard wound care
CI, Confidence interval; HBOT, hyperbaric oxygen therapy, RR, relative rition in recent years as an adjunct to facilitate wound healingfor diabetic foot ulcers and thus lower amputation rates.
Proponents contend that hyperbaric oxygen therapy pro-
motes wound healing through antiedema, antibacterial,
and neovascularization effects.Multiple small, nonrandom-
ized studies have pointed toward its effectiveness, but very
few randomized studies compare hyperbaric oxygen ther-
apy plus standard therapy with daily wound care including
dressing changes, local débridements, and amputations vs
standard therapy alone (Table II).64-67 Although differen-
tiation was typically not made between ischemic ulcers and
pressure-related ulcers, the authors showed statistically sig-
nificant improvements in amputation rates and wound
healing when hyperbaric oxygen was used.
The management goals of Charcot foot are to offload
the affected extremity, prevent further collapse and defor-
mity, and protect the opposite foot. The first step of treat-
ment is an extended period of nonweight bearing and cast-
or splint immobilization to promote eventual healing of the
joint. The use of accommodative footwear is essential to
long-term management. Surgery is rarely indicated, and a
stabilizing procedure is done most safely after the disease
has reached a quiescent stage. Amputation is reserved for
those rare patients with severe uncorrectable deformities,
those with chronic ulcers plagued by such extensive osteo-
myelitis that the foot is unsalvageable, or after failed open
reconstructions.
Patients with limb-threatening infections require im-
mediate hospitalization, immobilization, and intravenous
antibiotics. Cultures from the depths of the ulcer should be
sent; wound swabs are unreliable and should not be per-
formed. Empiric broad-spectrum antibiotic therapy should
be initiated to cover the polymicrobial infections usually
seen in diabetic patients.1,68 Empiric antibiotic regimens
are dictated by institutional preferences, local resistance
oxygen therapy to standard wound care
tment
ssions Reported results P
8  8 8.6% major amputation (RR, 0.26;
95% CI, 0.08-0.84)
.016
33.3% major amputation
30 62.5% ulcer healing
100% median2 wound area 6 wks .027
100% median2 wound area 6 mo NS
30 12.5% ulcer healing
52% median2 wound area 6 wks
95% median2 wound area 6 mo
20 Ulcer size decrease
42%  25% (day 15) .037
48%  30% (day 30) NS
22  17% (day 15)
42  27% (day 30)
0-90 66% healing without surgery .05
8% distal amputation .05
0% major amputation .05
0% healing with surgery .05
48% distal amputation .05
34% major amputation .05baric
Trea
se
38.
6patterns, availability, and cost. Numerous trials of antibiotic
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(Table III).68-73
The Study of Infections in Diabetic Feet Comparing
Efficacy, Safety, and Tolerability of Ertapenem Versus Pip-
eracillin/Tazobactam (SIDESTEP) is the largest and most
recent randomized, multicenter study. It evaluated one-
time-daily ertapenem vs four-times-daily piperacillin/
tazobactam inmoderate and severe diabetic foot infections.
Investigators were permitted to add vancomycin as needed
for methicillin-resistant Staphylococcus aureus (MRSA) en-
terococcus.73 This trial found no difference in eradication
rates, clinical outcomes, and adverse events between the
two regimens. Although all of these trials adequately com-
pared the various antibiotic regimens, they failed to focus
on an inherent weakness of simply using antibiotics alone;
that is, the reported “failure rates” in these trials of 11% to
12% for moderate infections and 19% to 30% for severe
infections.73 Furthermore, the presence of PAD predicts a
higher failure rate for healing any diabetic foot lesion 1
Table III. Summary of antibiotic trials for diabetic foot in
Author Antibiotic regimens Design Pa
Grayson,68
1994
Ampicillin/sulbactam Randomized,
double-blind,
single-center
Imipenem/cilastatin
Lipsky,69
2004
Linezolid IV or
PO;  aztreonam
Randomized,
open-label,
multicenter
241 (5
Ampicillin/sulbactam, or
amoxicillin/clavulanate
vancomycin or
aztreonam
120 (9
vanc
aztr
Clay,70
2004
Ceftriaxone 
metronidazole
Randomized,
open-label,
single-center
Ticarcillin/clavulanate
Harkless,71
2005
Piperacillin/tazobactam 
vancomycin
Randomized
open-label,
multicenter
Ampicillin/sulbactam 
vancomycin
Lipsky,72
2005
Daptomycin  aztreonam
or metronidazole
Randomized,
open-label,
multicenter
47 (38
Comparator (vancomycin or
vancomycin or
semi-synthetic PCN)
 aztreonam or
metronidazole
(41% a
Lipsky,73
2005
Ertapenem  vancomycin Randomized,
double-blind,
multicenter
295 (2
vanc
Piperacillin/tazobactam 
vancomycin
291 (1
vanc
CI, Confidence interval; IV, intravenous; PCN, penicillin; PO, oral adminisyear (31% failure vs 16% failure).74Numerous antibiotic regimens are appropriate as initial
therapy for limb-threatening infections. Given the increas-
ing prevalence of MRSA in hospital-acquired infections, as
well as in community isolates, empiric therapy with vanco-
mycin is warranted.75 Major advantages of fluoroquinolo-
nes are their potent activity against both gram-positive and
gram-negative organisms, the high tissue concentrations
obtained with oral administration, and the safety in penicillin-
allergic patients. Metronidazole can be added to cover
anaerobic bacteria against which fluoroquinolones have no
activity.76 Once culture results become available, antibiot-
ics should be appropriately tailored to prevent development
of resistance as well as to prevent unnecessary overuse and
even abuse of antibiotics. Mild infections usually require
only 7 to 10 days of antibiotic therapy, whereas moderate
and severe infections may require up to 3 weeks of treat-
ment.77
Traditional therapy for osteomyelitis was accepted as 4
to 6 weeks of intravenous antibiotics,78 but recent studies
ons
, No.
Treatment
duration
(days) Reported results 95% CI P
13  6.5 81% cure; 67%
eradication
NS
14.8  8.6 85% cure; 75%
eradication
reonam) 17.2  7.9 81% overall cure 0.1 to 20.1 NS
in, 2.5%
)
16.5  7.9 71% overall cure
44 72% treatment
success
NS
4 76% treatment
success
9 median 81% cure or
improvement
12.9 to 9.1 .124
10 median 83.1% cure or
improvement
reonam) 7-14 66% cure 14.4 to 21.8 NS
7-14 70% cure
)
)
nam)
in)
11.1 87% favorable
clinical response
6.3 to 9.1 NS
in)
11.3 83% favorable
clinical response
.fecti
tients
48
48
% azt
.6%
omyc
eonam
36
34
155
159
% azt
56
(29
(27
ztreo
.3%
omyc
.7%
omyc
trationhave documented a 30% recurrence rate using this mo-
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vated creatinine, prior hospitalization for foot lesion, and
gangrene.79 In fact, even though proponents point to their
70% success in avoiding surgery, the treatment with antibi-
otics can take up to 1 or 2 years to achieve this success.81-83
On the other hand, aggressive surgical débridement of
infected bone shortens healing times, decreases the need
for long-term antibiotic therapy, limits the emergence of
resistant bacteria, and reduces inpatient and outpatient
economic costs.84,85 Unfortunately, the data to support
this surgical dogma are limited to single-center retrospec-
tive studies, and no randomized trials exist to adequately
settle this debate.
SURGICAL AND ENDOVASCULAR
TREATMENT
Patients with abscess formation or necrotizing fasciitis
must undergo prompt incision, drainage, and débride-
ment, including partial open toe, ray, or forefoot amputa-
tion.86 Tendon sheaths should be probed as proximally as
possible and excised if infected. Despite fears to the con-
trary, long and extensive drainage incisions will heal when
infection is controlled and foot circulation is adequate.
Limb salvage is 89.8% at 1 year and 82.3% at 5 years after an
initial minor amputation.87 It is imperative to make any
necessary incision initially but at the same time to contem-
plate the implications of those incisions on the potential
completion amputation. Wounds should be packed open
with saline-moistened gauze, and dressings should be
changed two to three times a day. Wounds should be
examined daily, and additional bedside or operative
débridement should be repeated as needed. Adequate de-
pendent drainage is crucial, and limited incisions with
closed-suction or Penrose drains should be avoided.
Numerous adjunctive modalities exist for wound care,
such as topical growth factors, synthetic skin grafts, electri-
cal stimulation, hyperbaric oxygen chambers, and negative-
pressure wound therapy. Each has its own merits, but
economic constraints and patient compliance should be
kept in mind when comparing these with the well-established
modality of simple gauze dressings. Multiple small trials
have indicated that negative-pressure wound therapy is at
least as good as or better than current local treatment
options.88
A recent randomized trial involving 162 diabetic pa-
tients revealed the efficacy of the vacuum-assisted closure
negative-pressure wound therapy system (V.A.C.; KCI
Medical, San Antonio, Tex) compared with standard moist
gauze dressings. In diabetic patients with partial foot am-
putations and adequate perfusion, V.A.C. therapy resulted
in a higher proportion of healed wounds (56% vs 39%, P
.04), faster healing rates (median time to closure, 56 vs 77
days; P  .005), and potentially fewer reamputations than
standard care (3% vs 11%, P .06).89 The average total cost
to achieve healing was $25,954 in the V.A.C. group com-
pared with $38,806 in the control group, mainly due to
fewer surgical procedures performed, fewer dressing
changes, and fewer outpatient treatment visits in theV.A.C. group.90 Another recent multicenter randomized
trial of 335 diabetic patients similarly confirmed the supe-
riority of the V.A.C. system compared with standard moist
dressings for complete ulcer closure (43% vs 29%, P 
.007), median time to closure (96 days vs not determinable,
P .001), and subsequent amputation rate (4.1% vs 10.2%,
P  .035).91
From a revascularization perspective, the most impor-
tant difference in lower extremity atherosclerosis in the
diabetic patient is the anatomic location or distribution of
the arterial lesions.12 Although diabetic patients who abuse
nicotine may manifest iliac or femoral occlusive disease,
they typically have significant occlusive disease in the infr-
apopliteal arteries, but arteries of the foot are spared.92 This
“tibial artery disease” requires a different approach to arte-
rial reconstruction and presents special challenges for the
surgeon.
Each operationmust be individualized according to the
patient’s available venous conduit and arterial anatomy. In
10% of patients, a foot artery, usually the dorsalis pedis
artery, is the only suitable outflow vessel; in an additional
15%, the dorsalis pedis artery will appear to be the best
target vessel compared with other patent but diseased tibial
vessels.93 In one of the most comprehensive studies to date
on dorsalis pedis revascularization in diabetic patients,
Pomposelli et al94 reported results from 1000 bypasses
spanning a decade, with diabetic patients comprising 92%
of the cohort. Primary patency, secondary patency, and
limb salvage rates were 56.8%, 62.7%, and 78.2% at 5 years
and 37.7%, 41.7%, and 57.7% at 10 years. Patient survival
was 48.6% at 5 years and 23.8% at 10 years, and perioper-
ative mortality was only 0.9%. The popliteal artery was the
source of inflow in 53.2% of patients.
Even in the presence of foot infection, pedal bypass can
be performed safely as long as invasive sepsis is controlled
before surgery.57 Although pedal bypass represents the
most “extreme” type of distal arterial reconstruction, it is
almost always possible, particularly when the surgeon is
flexible in terms of venous conduit and location of proximal
anastomosis.
Initially designed to study the effects of an E2F decoy
on vein graft failure, the Edifoligide for the Prevention of
Infrainguinal Vein Graft Failure (PREVENT III) trial con-
stitutes the largest prospective, randomized study of vein
bypass grafts for critical limb ischemia performed to date,
and the overall surgical results serve as a benchmark for
current practice.95 For these 1404 patients, of which 64%
were diabetic, 75% had tissue loss, 65% had infrapopliteal
targets, and 24% had high-risk conduit. Early graft failure
occurred in 5.2%. After 1 year, primary patency was 61%,
secondary patency was 80%, limb salvage was 88%, and
overall survival was 84%. The factors negatively affecting
patency were high-risk conduit (nonsingle segment of great
saphenous vein or diameter3 mm) and African American
race.
Although these results94,95 justify surgical reconstruc-
tion as the current gold standard for diabetic foot revascu-
larization, endovascular intervention has become a useful
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 2 Kalish and Hamdan 483alternative. With the potential pitfalls accompanying tradi-
tional surgical approaches to limb salvage, as well as the
overall poor health and life expectancy of patients with
PAD, less invasive endovascular therapy can represent an
attractive option. Balloon angioplasty and stenting are well
suited to focal, short-segment iliac stenoses or occlusions,
which exist in 10% to 20% of diabetic patients.96
The morbidity of open surgery for outflow procedures
can be quite significant and not simply limited to local
wound complications or myocardial infarctions. Readmis-
sions to the hospital, reoperations, slow time to healing,
and time spent in rehabilitation must be factored into the
risk-benefit analysis.97 In fact, the ideal outcome—patent
graft, healed wound, and no additional operations in a fully
ambulatory patient who can sustain independent living—
may only be obtainable 14% to 22% of the time at a mean
follow-up of 42 months.98 Although patency rates of by-
pass grafts have been shown to be equivalent in diabetic and
nondiabetic patients,94 endovascular interventions may be
associated with worse patency rates in diabetic patients
(53% vs 71% at 12 months, 49% vs 58% at 18 months; P 
.05) due to their higher prevalence of limb-threatening
ischemia as the presenting symptom.99
The TransAtlantic Inter-Society Consensus Working
Group (TASC) initially stratified femoropopliteal and tibial
lesions in 2000 and made recommendations for therapy
based on lesion type (stenosis vs occlusion), location, and
length.96 The best scientific attempt to compare primary
open and endovascular interventions was the Bypass Versus
Angioplasty in Severe Ischemia of the Leg (BASIL) trial
(Table IV).100 Although only 42% of the patients had
diabetes, the level of ischemia in these 452 randomized
patients was comparable with the typical disease patterns
seen in a diabetic patient population. Perioperative (30-
day) morbidity was higher with surgery, and all-cause mor-
tality trended higher with surgery for the first 6 months but
then trended lower for the next 6months. Amputation-free
survival was similar in both groups. Two-year post hoc
analysis revealed that surgery was associated with a reduced
Table IV. Summary of the Bypass Versus Angioplasty in S
Procedure Demographics Morbidity
PTA 224 pts (42% diabetic) 41% overalla 5%
92% rest pain 2.5% MI
75% tissue loss 7.6% wound infection 39%
20% immediate
technical failurea
28% reinterventiona
Bypass 228 pts (42% diabetic) 57% overalla 3%
90% rest pain 6.6% MI 35%
73% tissue loss 22.9% wound infection
3% immediate technical
failurea
17% reinterventiona
MI, Myocardial infarction; PTA, percutaneous transluminal angioplasty.
aStatistically significant difference.risk of future amputation, or death, or both.The trialists concluded that although the strategies are
roughly equivalent for mortality and amputation-free sur-
vival at medium-term follow-up, angioplasty should be
used first for patients with significant comorbidities and
with a life expectancy of 1 to 2 years. Moreover, longer-
term results favor surgery over angioplasty if there is a
“good” vein and a medically fit patient.101 More recent
reviews have shown that after 2 years, tibial angioplasty
requires repeat endovascular intervention in 28% of patients
(72% of studied patients were diabetic), and another 15% of
patients go on to have a surgical bypass, with TASC D
lesions predicting the highest failure rate.102
The presence of renal failure presents special chal-
lenges. If acute renal failure occurs, which most commonly
happens after contrast arteriography, surgery is delayed
until renal function has stabilized or returned to baseline.
Patients with end-stage renal disease who require dialysis
can safely undergo arterial reconstruction with reasonable
graft patency rates (primary patency, 60%; secondary pa-
tency, 86%) and with limb salvage rates up to 80%.103,104
Gangrene and tissue loss are frequent, however, and the
healing response is poor, even with restoration of arterial
blood flow. Graft patency and limb salvage in these patients
are lower compared with patients without renal failure, and
30% to 50% may come to amputation with a patent bypass
graft.105,106 Long-term survival is poor for this group, with
3-year survival of 18% and 5-year survival of only 5%.104 As
a result of this poor survival, many institutions prefer a
complete endovascular approach to patients with renal
failure, despite the lower limb salvage rates.107,108
A final aspect of managing diabetic foot ulcers is off-
loading to decrease pressure on the extremity. Offloading
strategies involve combinations of bed rest, crutches or
wheelchairs, casting, foams or padding, and healing shoes
or walking boots. Only after wound healing has been
achieved should weight bearing be reinstituted back to
baseline levels, and consultation with a physical therapist
should be obtained when necessary.
The last alternative remains amputation. Closed minor
e Ischemia of the Leg (BASIL) trial
ortality
Amputation-free
survival
Hospital data (cost first
12 months)
ay 71% 1-year £17,419
52% 3-year
nd of follow-up Total days in hospital  36a
ay 68% 1-year £23,322
nd of follow-up 57% 3-year
Total days in hospital  46aever
M
30-d
at e
30-d
at etoe or transmetatarsal amputations are practical after infec-
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patient with a functional foot for walking. In situations
involving extensive tissue loss precluding a functional foot,
when there are nonhealing wounds in the setting of patent
grafts and for control of sepsis, amputation below the knee
is necessary.109 Surgeons should strive to preserve the knee
joint because of its functional significance for rehabilitation,
with 34% to 62% of below-knee amputees ambulating
postoperatively vs 9% to 23% of above-knee ampu-
tees.110,111 Above-knee amputations are reserved for debil-
itated patients with severe tissue loss or with no capacity to
ambulate.109 Because of modern advances in prostheses
coupled with aggressive approaches to rehabilitation, am-
putation should be viewed as an acceptable modality to
treat diabetic foot complications and not as a treatment
failure.
AUTHOR CONTRIBUTIONS
Conception and design: JK, AH
Analysis and interpretation: JK, AH
Data collection: JK, AH
Writing the article: JK, AH
Critical revision of the article: JK, AH
Final approval of the article: JK, AH
Statistical analysis: JK, AH
Obtained funding: Not applicable
Overall responsibility: AH
REFERENCES
1. Gibbons GW, Eliopoulos GM. Infection of the diabetic foot. In:
Kozak GP, Campbell DR, Frykberg RG, Habershaw GM, editors.
Management of diabetic foot problems, 2nd edition. Philadelphia: WB
Saunders, 1995. p. 121-9.
2. National Institute of Diabetes and Digestive and Kidney Diseases.
National Diabetes Statistics fact sheet: general information and na-
tional estimates on diabetes in the United States, 2007. http://
diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm. Accessed:
Jul 18, 2009.
3. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health
care costs of diabetic peripheral neuropathy in the U.S. Diabetes Care
2003;26:1790-5.
4. Prompers L, Huijberts M, Schaper N, Apelqvist J, Bakker K, Edmonds
M, et al. Resource utilization and costs associated with the treatment of
diabetic foot ulcers. Prospective data from the Eurodiale Study. Dia-
betologia 2008;51:1826-34.
5. Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM,
Kravitz SR, et al. Diabetic foot disorders. A clinical practice guideline
(2006 revision). J Foot Ankle Surg 2006;45(5 suppl):S1-S66.
6. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients
with diabetes. JAMA 2005;293:217-28.
7. Ramsey SD, Newton K, Blough D,McCulloch DK, Sandhu N, Reiber
GE, Wagner EH. Incidence, outcomes, and cost of foot ulcers in
patients with diabetes. Diabetes Care 1999;22:382-7.
8. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM; American
Diabetes Association. Preventive foot care in diabetes. Diabetes Care
2004;27:S63-4.
9. Boulton AJM, Vileikyte L, Ragnarson G, Apelqvist J. The global
burden of diabetic foot disease. Lancet 2005;366:1719-24.
10. Goldenberg SG, Alex M, Joshi RA, Blumenthal HT. Nonatheroma-
tous peripheral vascular disease of the lower extremity in diabetes
mellitus. Diabetes 1959;8:261-73.
11. Strandness DE, Priest RE, Gibbons GW. Combined clinical and
pathological study of diabetic and nondiabetic peripheral arterial dis-
ease. Diabetes 1964;13:366-72.12. LoGerfo FW, Coffman JD. Current concepts. Vascular and microvas-
cular disease of the foot in diabetes. Implications for foot care. N Engl
J Med 1984;311:1615-9.
13. Kozak GP, Giurini R. Diabetic neuropathies: lower extremities. In:
Kozak GP, Campbell DR, Frykberg RG, Habershaw GM, editors.
Management of diabetic foot problems. 2nd ed. Philadelphia: WB
Saunders; 1995. p. 43-52.
14. Gabbay KH. The sorbitol pathway and the complications of diabetes.
N Engl J Med 1973;288:831-6.
15. Boulton AJ, Scarpello JH, Ward JD. Venous oxygenation in the
diabetic neuropathic foot: evidence of arteriovenous shunting? Diabe-
tologia 1982;22:6-8.
16. Arora S, Smakowski P, Frykberg RG, Simeone LR, Freeman R,
LoGerfo FW, et al. Differences in foot and forearm skin microcircula-
tion in diabetic patients with and without neuropathy. Diabetes Care
1998;21:1925-34.
17. deMeijer VE, Van’t Sant HP, Spronk S, Kusters FJ, den Hoed PT.
Reference value of transcutaneous oxygen measurement in diabetic
patients compared with nondiabetic patients. J Vasc Surg 2008;48:
382-8.
18. LeinonenH,Matikainen E, Juntunen J. Permeability andmorphology
of skeletal muscle capillaries in type 1 (insulin-dependent) diabetes
mellitus. Diabetologia 1982;22:158-62.
19. Rayman G, Williams SA, Spencer PD, Smaje LH, Wise PH, Tooke JE.
Impaired microvascular hyperaemic response to minor skin trauma in
type I diabetes. Br Med J 1986;292:1295-8.
20. Parkhouse N, Le Quesne PM. Impaired neurogenic vascular response
in patients with diabetes and neuropathic foot lesions. N Engl J Med
1988;318:1306-9.
21. Kannel WB, McGee DL. Update on some epidemiologic features of
intermittent claudication: the Framingham Study. J Am Geriatr Soc
1985;33:13-8.
22. Johannesson A, LarssonGU, RamstrandN, Turkiewicz A,Wiréhn AB,
Atroshi I. Incidence of lower-limb amputation in the diabetic and
nondiabetic general population: a 10-year population-based cohort
study of initial unilateral and contralateral amputations and reamputa-
tions. Diabetes Care 2009;32:275-80.
23. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis:
epidemiology, pathophysiology, and management. JAMA 2002;287:
2570-81.
24. Vinik AI, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB, Colen
LB. Diabetic neuropathies. Diabetes Care 1992;15:1926-75.
25. Casellini CM, Vinik AI. Clinical manifestations and current treatment
options for diabetic neuropathies. Endocr Pract 2007;13:550-66.
26. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes
M, et al. Gabapentin for the symptomatic treatment of painful neu-
ropathy in patients with diabetes mellitus: a randomized controlled
trial. JAMA 1998;280:1831-6.
27. Serpell MG; Neuropathic pain study group. Gabapentin in neu-
ropathic pain syndromes: a randomised, double-blind, placebo-
controlled trial. Pain 2002;99:557-66.
28. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves
symptoms of painful diabetic neuropathy: a randomized controlled
trial. Neurology 2004;63:2104-10.
29. Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr.
Pregabalin for relief of neuropathic pain associated with diabetic
neuropathy: a randomized, double-blind study. Eur J Pain 2008;12:
203-13.
30. Wernicke JF, Pritchett YL, D’Souza DN,Waninger A, Tran P, Iyengar
S, et al. A randomized controlled trial of duloxetine in diabetic
peripheral neuropathic pain. Neurology 2006;67:1411-20.
31. Raskin J, Pritchett YL, Wang F, D’Souza DN, Waninger AL, Iyengar
S, et al. A double-blind, randomized multicenter trial comparing
duloxetine with placebo in the management of diabetic peripheral
neuropathic pain. Pain Med 2005;6:346-56.
32. Tan JS, Anderson JL, Watanakunakorn C, Phair JP. Neutrophil dys-
function in diabetes mellitus. J Lab Clin Med 1975;85:26-33.
33. Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in
patients with poorly controlled diabetes. Diabetes 1974;23:9-15.
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 2 Kalish and Hamdan 48534. Lipsky BA.New developments in diagnosing and treating diabetic foot
infections. Diabetes Metab Res Rev 2008;24(S1):S66-S71.
35. Lavery LA, Armstrong DG, Murdoch DP, Peters EJ, Lipsky BA.
Validation of the infectious diseases society of America’s diabetic foot
classification system. Clin Infect Dis 2007;44:562-5.
36. Lavery LA, Peters EJ, Armstrong DG, Wendel CS, Murdoch DP,
Lipsky BA. Risk factors for developing osteomyelitis in patients with
diabetic foot wounds. Diabetes Res Clin Pract 2009;83:347-52.
37. Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical
examination and imaging tests for osteomyelitis underlying diabetic
foot ulcers: meta-analysis. Clin Infect Dis 2008;47:519-27.
38. Lavery LA, Armstrong DG, Peters EJ, Lipsky BA. Probe-to-bone test
for diagnosing diabetic foot osteomyelitis: reliable or relic? Diabetes
Care 2007;30:270-4.
39. Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW.
Probing to bone in infected pedal ulcers. A clinical sign of underlying
osteomyelitis in diabetic patients. JAMA 1995;273:721-3.
40. Marcus CD, Ladam-Marcus VJ, Leone J, Malgrange D, Bonnet-
Gausserand FM, Menanteau BP. MR imaging of osteomyelitis and
neuropathic osteoarthropathy in the feet of diabetics. Radiographics
1996;16:1337-48.
41. Butalia S, Palda VA, Sargeant RJ, Detsky AS, Mourad O. Does this
patient with diabetes have osteomyelitis of the lower extremity? JAMA
2008;299:806-13.
42. Stein R, Hriljac I, Halperin JL, Gustavson SM, Teodorescu V, Olin
JW. Limitation of the resting ankle-brachial index in symptomatic
patients with peripheral arterial disease. Vasc Med 2006;11:29-33.
43. Weitz JI, Byrne J, Clagett GP, FarkouhME, Porter JM, Sackett DL, et
al. Diagnosis and treatment of chronic arterial insufficiency of the
lower extremities: a critical review. Circulation 1996;94:3026-49.
44. Potier L, HalbronM, Bouilloud F, DadonM, Le Doeuff J, Ha Van G,
et al. Ankle-to-brachial ratio index underestimates the prevalence of
peripheral occlusive disease in diabetic patients at high risk for arterial
disease. Diabetes Care 2009;32:e44.
45. Hauser CJ, Klein SR, Mehringer CM, Appel P, Shoemaker WC.
Superiority of transcutaneous oximetry in noninvasive vascular diag-
nosis in patients with diabetes. Arch Surg 1984;119:690-4.
46. Carpenter JP, Baum RA, Holland GA, Barker CF. Peripheral vascular
surgery with magnetic resonance angiography as the sole preoperative
imaging modality. J Vasc Surg 1994;20:861-9; discussion 869-71.
47. Shabana WM, Cohan RH, Ellis JH, Hussain HK, Francis IR, Su LD,
et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J
Roentgenol 2008;190:736-41.
48. Toprak O, Cirit M, Yesil M, Bayata S, Tanrisev M, Varol U, et al.
Impact of diabetic and pre-diabetic state on development of contrast-
induced nephropathy in patients with chronic kidney disease. Nephrol
Dial Transplant 2007;22:819-26.
49. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis
of the renal safety of isosmolar iodixanol compared with low-osmolar
contrast media. J Am Coll Cardiol 2006;48:692-9.
50. Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR. Sodium
bicarbonate therapy for prevention of contrast-induced nephropathy:
a systematic review and meta-analysis. Am J Kidney Dis 2009;53:
617-27.
51. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ,
et al. Nephrotoxic effects in high-risk patients undergoing angiogra-
phy. N Engl J Med 2003;348:491-9.
52. Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, et al. Renal
toxicity evaluation and comparison between visipaque (iodixanol) and
hexabrix (ioxaglate) in patients with renal insufficiency undergoing
coronary angiography: the RECOVER study: a randomized con-
trolled trial. J Am Coll Cardiol 2006;48:924-30.
53. Coyle LC, Rodriguez A, Jeschke RE, Simon-Lee A, Abbott KC,
Taylor AJ. Acetylcysteine In Diabetes (AID): a randomized study of
acetylcysteine for the prevention of contrast nephropathy in diabetics.
Am Heart J 2006;151:1032.e9-12.
54. Gibbons GW, Wheelock FC, Hoar CS, Rowbotham JL, Siembieda C.
Predicting success of forefoot amputations in diabetics by noninvasive
testing. Arch Surg 1979;114:1034-6.55. Pomposelli FB, Arora S, Gibbons GW, Frykberg R, Smakowski P,
Campbell DR, et al. Lower extremity arterial reconstruction in the very
elderly: successful outcome preserves not only the limb but also
residential status and ambulatory function. J Vasc Surg 1998;28:
215-25.
56. Hnath J, Roddy SP, Darling RC, Paty PS, Taggert JB, Mehta M.
Comparative results of open lower extremity revascularization in no-
nagenarians. J Vasc Surg 2009;49:1459-64.
57. Tannenbaum GA, Pomposelli FB, Marcaccio EJ, Gibbons GW,
Campbell DR, Freeman DV, et al. Safety of vein bypass grafting to the
dorsal pedal artery in diabetic patients with foot infections. J Vasc Surg
1992;15:982-8; discussion 1989-90.
58. Treiman GS, Oderich GS, Ashrafi A, Schneider PA. Management of
ischemic heel ulceration and gangrene: an evaluation of factors associ-
ated with successful healing. J Vasc Surg 2000;31:1110-8.
59. Berceli SA, Chan AK, Pomposelli FP, Gibbons GW, Campbell DR,
Akbari CM, et al. Efficacy of dorsal pedal artery bypass in limb salvage
for ischemic heel ulcers. J Vasc Surg 1999;30:499-508.
60. Cook J, Cook E, Landsman AS, Basile P, Dinh T, Lyons T, et al. A
retrospective assessment of partial calcanectomies and factors influenc-
ing postoperative course. J Foot Ankle Surg 2007;46:248-55.
61. Jeffcoate WJ, Harding KG: Diabetic foot ulcers. Lancet 2003;361:
1545-51.
62. Lincoln NB, Radford KA, Game FL, Jeffcoate WJ. Education for
secondary prevention of foot ulcers in people with diabetes: a random-
ised controlled trial. Diabeteologia 2008;51:1954-61.
63. Tyrrell W. Orthotic intervention in patients with diabetic foot ulcer-
ation. J Wound Care 1999;8:530-2.
64. Faglia E, Favales F, Aldeghi A, Calia P, Quarantiello A, Oriani G, et al.
Adjunctive systemic hyperbaric oxygen therapy in treatment of severe
prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes
Care 1996;19:1338-43.
65. Abidia A, Laden G, Kuhan G, Johnson BF, Wilkinson AR, Renwick
PM, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic
lower extremity ulcers: a double-blind randomised-controlled trial.
Eur J Vasc Endovasc Surg 2003;25:513-8.
66. Kessler L, Bilbault P, Ortega F, Grasso C, Passemard R, Stephan D, et
al. Hyperbaric oxygenation accelerates the healing rate of nonischemic
chronic diabetic foot ulcers: a prospective randomized study. Diabetes
Care 2003;26:2378-82.
67. Duzgun AP, Satir HZ, Ozozan O, Saylam B, Kulah B, Coskun F.
Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers.
J Foot Ankle Surg 2008;47:515-9.
68. Grayson ML, Gibbons GW, Habershaw GM, Freeman DV, Pom-
poselli FB, Rosenblum BI, et al. Use of ampicillin/sulbactam versus
imipenem/cilastatin in the treatment of limb-threatening foot infec-
tions in diabetic patients. Clin Infect Dis 1994;18:683-93.
69. Lipsky BA, Itani K, Norden C; Linezolid Diabetic Foot Infections Study
Group. Treating foot infections in diabetic patients: a randomized, mul-
ticenter, open-label trial of linezolid versus ampicillin-sulbactam/
amoxicillin-clavulanate. Clin Infect Dis 2004;38:17-24.
70. Clay PG, Graham MR, Lindsey CC, Lamp KC, Freeman C, Glaros A.
Clinical efficacy, tolerability, and cost savings associated with the use of
open-label metronidazole plus ceftriaxone once daily compared with
ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic
lower-extremity infections in older males. Am J Geriatr Pharmacother
2004;2:181-9.
71. Harkless L, Boghossian J, Pollak R, CaputoW, Dana A, Gray S, WuD.
An open-label, randomized study comparing efficacy and safety of
intravenous piperacillin/tazobactam and ampicillin/sulbactam for in-
fected diabetic foot ulcers. Surg Infect (Larchmt) 2005;6:27-40.
72. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected dia-
betic foot ulcers: evidence from a randomized, controlled trial com-
paring daptomycin with vancomycin or semi-synthetic penicillins for
complicated skin and skin-structure infections. J Antimicrob Che-
mother 2005;55:240-5.
73. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstrn DE,
AbramsonMA. Ertapenem versus piperacillin/tazobactam for diabetic
foot infections (SIDESTEP): prospective, randomised, controlled,
double-blinded, multicentre trial. Lancet 2005;366:1695-703.
JOURNAL OF VASCULAR SURGERY
February 2010486 Kalish and Hamdan74. Prompers L, Schaper N, Apelqvist J, EdmondsM, Jude E,Mauricio D,
et al. Prediction of outcome in individuals with diabetic foot ulcers:
focus on the differences between individuals with and without periph-
eral arterial disease. The EURODIALE Study. Diabetologia 2008;51:
747-55.
75. Lipsky BA. Empirical therapy for diabetic foot infections: are there
clinical clues to guide antibiotic selection? Clin Microbiol Infect
2007;13:351-3.
76. Ellison MJ. Vancomycin, metronidazole, and tetracyclines. Clin Podi-
atr Med Surg 1992;9:425-42.
77. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer
AW, et al. Diagnosis and treatment of diabetic foot infections. Clin
Infect Dis 2004;39:885-910.
78. Bamberger DM, Daus GP, Gerding DN. Osteomyelitis in the feet of
diabetic patients: long-term results, prognostic factors, and the role of
antimicrobial and surgical therapy. Am J Med 1987;83:653-60.
79. Pittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD.
Outcome of diabetic foot infections treated conservatively: a retro-
spective cohort study with long-term follow-up. Arch Intern Med
1999;159:851-6.
80. Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis
among patients treated with outpatient parenteral antimicrobial ther-
apy. Am J Med 2003;114:723-8.
81. Senneville E, Lombart A, Beltrand E, Valette M, Legout L, Cazaubiel
M, et al. Outcome of diabetic foot osteomyelitis treated nonsurgically:
a retrospective cohort study. Diabetes Care 2008;31:637-42.
82. Game FL, Jeffcoate WJ. Primarily non-surgical management of osteo-
myelitis of the foot in diabetes. Diabetologia 2008;51:962-7.
83. Venkatesan P, Lawn S, Macfarlane RM, Fletcher EM, Finch RG,
Jeffcoate WJ. Conservative management of osteomyelitis in the feet of
diabetic patients. Diabet Med 1997;14:487-90.
84. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect
Dis 1997;25:1318-26.
85. Ha Van G, Siney H, Danan JP, Sachon C, Grimaldi A. Treatment of
osteomyelitis in the diabetic foot. Contribution of conservative sur-
gery. Diabetes Care 1996;19:1257-60.
86. Gibbons GW. The diabetic foot: amputations and drainage of infec-
tion. J Vasc Surg 1987;5:791-3.
87. Sheahan MG, Hamdan AD, Veraldi JR, McArthur CS, Skillman JJ,
Campbell DR, et al. Lower extremity minor amputations: the roles of
diabetes mellitus and timing of revascularization. J Vasc Surg 2005;
42:476-80.
88. Vikatmaa P, Juutilainen V, Kuukasjarvi P, Malmivaara A. Negative
pressure wound therapy: a systematic review on effectiveness and
safety. Eur J Vasc Endovasc Surg 2008;36:438-48.
89. Armstrong DG, Lavery LA; Diabetic Foot Study Consortium. Nega-
tive pressure wound therapy after partial diabetic foot amputation: a
multicentre, randomised controlled trial. Lancet 2005;366:1704-10.
90. Apelqvist J, Armstrong DG, Lavery LA, Boulton AJ. Resource utiliza-
tion and economic costs of care based on a randomized trial of
vacuum-assisted closure therapy in the treatment of diabetic foot
wounds. Am J Surg 2008;195:782-8.
91. Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of
negative pressure wound therapy using vacuum-assisted closure with
advancedmoist wound therapy in the treatment of diabetic foot ulcers:
a multicenter randomized controlled trial. Diabetes Care 2008;31:
631-6.
92. Ciavarella A, Silletti A, Mustacchio A, Gargiulo M, Galaverni MC,
Stella A, Vannini P. Angiographic evaluation of the anatomic pattern
of arterial obstructions in diabetic patients with critical limb ischemia.
Diabet Metab 1993;19:586-9.
93. Pomposelli FB, Jepsen SJ, Gibbons GW, Campbell DR, Freeman DV,
Miller A, et al. Efficacy of the dorsal pedal bypass for limb salvage in
diabetic patients: short-term observations. J Vasc Surg 1990;11:
745-51.94. Pomposelli FB, Kansal N, Hamdan AD, Belfield A, Sheahan M,
Campbell DR, et al. A decade of experience with dorsalis pedis artery
bypass: analysis of outcome in more than 1000 cases. J Vasc Surg
2003;37:307-15.
95. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ,
et al. Results of PREVENT III: a multicenter, randomized trial of
edifoligide for the prevention of vein graft failure in lower extremity
bypass surgery. J Vasc Surg 2006;43:742-51.
96. Dormandy JA, Rutherford RB. Management of peripheral arterial
disease (PAD): TASCWorking Group. J Vasc Surg 2000;31:S1-S296.
97. Goshima KR, Mills JL, Hughes JD. A new look at outcomes after
Infrainguinal bypass surgery: traditional reporting standards systemat-
ically underestimate the expenditure of effort required to attain limb
salvage. J Vasc Surg 2004;39:330-5.
98. Nicoloff AD, Taylor LM, McLafferty RB, Moneta GL, Porter JM, et
al. Patient recovery after infrainguinal bypass grafting for limb salvage.
J Vasc Surg 1998;27:256-63.
99. DeRubertis BG, Pierce M, Ryer EJ, Trocciola S, Kent KC, Faries PL.
Reduced primary patency rate in diabetic patients after percutane-
ous intervention results from more frequent presentation with limb-
threatening ischemia. J Vasc Surg 2008;47:101-8.
100. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et
al.; BASIL trial participants. Bypass versus angioplasty in severe isch-
aemia of the leg (BASIL): multicentre, randomised controlled trial.
Lancet 2005;366:1925-34.
101. Beard JD.Which is the best revascularization for critical limb ischemia:
Endovascular or open surgery? J Vasc Surg 2008;48(6 suppl):11-6S.
102. Giles KA, Pomposelli FB, Hamdan AD, Blattman SB, Panossian H,
Schermerhorn ML. Infrapopliteal angioplasty for critical limb isch-
emia: relation of TransAtlantic InterSociety Consensus class to out-
come in 176 limbs. J Vasc Surg 2008;48:128-36.
103. Lantis JC, Conte MS, Belkin M, Whittemore AD, Mannick JA,
Donaldson MC. Infrainguinal bypass grafting in patients with end-
stage renal disease: improving outcomes? J Vasc Surg 2001;33:
1171-8.
104. Ramdev P, Rayan SS, Sheahan M, Hamdan AD, Logerfo FW, Akbari
CM, et al. A decade experience with infrainguinal revascularization in
a dialysis-dependent patient population. J Vasc Surg 2002;36:969-74.
105. Korn P, Hoenig SJ, Skillman JJ, Kent KC. Is lower extremity revascu-
larization worthwhile in patients with end- stage renal disease? Surgery
2000;128:472-9.
106. Johnson BL, Glickman MH, Bandyk DF, Esses GE. Failure of foot
salvage in patients with end-stage renal disease after surgical revascu-
larization. J Vasc Surg 1995;22:280-6.
107. Aulivola B, GargiuloM, BessoniM, Rumolo A, Stella A. Infrapopliteal
angioplasty for limb salvage in the setting of renal failure: do results
justify its use? Ann Vasc Surg 2005;19:762-8.
108. Graziani L, Silvestro A, Bertone V, Manara E, Alicandri A, Parrinello
G, et al. Percutaneous transluminal angioplasty is feasible and effective
in patients on chronic dialysis with severe peripheral arterial disease.
Nephrol Dial Transplant 2007;22:1144-99.
109. Abou-Zamzam AM, Gomez NR, Molkara A, Banta JE, Teruya TH,
Killeen JD, et al. A prospective analysis of critical limb ischemia: factors
leading to major primary amputation versus revascularization. Ann
Vasc Surg 2007;21:458-63.
110. Nehler MR, Coll JR, Hiatt WR. Functional outcome in a contempo-
rary series of major lower extremity amputations. J Vasc Surg 2003;
38:7-14.
111. Toursarkissian B, Shireman PK, Harrison A, D’Ayala M, Schoolfield J,
Sykes MT. Major lower-extremity amputation: contemporary experi-
ence in a single Veterans Affairs institution. Am Surg 2002;68:606-10.Submitted Jun 24, 2009; accepted Aug 12, 2009.
